Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.55 |
| ▸ | CNR2 | P34972 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23520505 | 1.00 | CNR1 (0.55) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3707641 | 1.00 | CNR1 (0.55) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL20086312 | 0.93 | CNR1 (0.50) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL2783735 | 0.89 | ALDH1A1 (0.44) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL2783732 | 0.89 | ALDH1A1 (0.44) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL20086304 | 0.87 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL21052408 | 0.86 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL21052409 | 0.86 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL21052411 | 0.85 | ALDH1A1 (0.49) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL21052413 | 0.85 | ALDH1A1 (0.49) | CNR1CNR2ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | claimed |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-08-07 | — | — | US | disclosed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | CNR1 119/4885CNR2 35/4885ALDH1A1 695/4885 |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | CNR1 103/4885CNR2 33/4885ALDH1A1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.